Hillhouse, Quan lead $93M series B for immuno-oncology play NextCure
By Elizabeth S. Eaton | Nov 16, 2018 | 3:55 PM GMT
NextCure Inc. (Beltsville, Md.) raised $93 million on Nov. 13 in a series B round led by new investors Hillhouse Capital Management and Quan Capital to fund development of its two lead immuno-oncology candidates.
PD-1 pioneer Lieping
Read the full 361 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD